MAML2 (mastermind like transcriptional coactivator 2) functions as a transcriptional coactivator that potentiates NOTCH-induced gene expression, particularly of target genes like HES1 1. While MAML2's primary role involves NOTCH signaling pathway regulation, it has significant clinical relevance as a component of recurrent gene fusions in multiple tumor types. The CRTC1-MAML2 fusion oncogene, resulting from t(11;19) translocation, is a hallmark molecular feature of mucoepidermoid carcinoma (MEC) and acts as a transcription factor disrupting normal cell-cycle and differentiation pathways 1. MAML2 fusion detection demonstrates high diagnostic utility: CRTC1/3::MAML2 fusions show 100% sensitivity and 70.59% specificity in distinguishing intraosseous mucoepidermoid carcinoma from glandular odontogenic cyst 2. Beyond MEC, MAML2 participates in fusion events across diverse neoplasms, including YAP1::MAML2 fusions in sweat gland tumors (hidradenoma, hidradenocarcinoma, poroid tumors) 3, hemangioendothelioma 4, and myxoinflammatory fibroblastic sarcoma 5. Molecular testing for MAML2 gene rearrangements via FISH, RT-PCR, or NGS represents a valuable diagnostic aid in distinguishing these rare malignancies from morphologically similar entities 6, with potential prognostic implications in MEC management 1.